Literature DB >> 7729598

Induction of Xenopus oocyte meiotic maturation by MAP kinase.

O Haccard1, A Lewellyn, R S Hartley, E Erikson, J L Maller.   

Abstract

Mitogen-activated protein kinase (MAPK) is one of the protein kinases activated during meiotic maturation of Xenopus laevis oocytes. The c-Mosxe protein kinase, which has been shown to be sufficient to promote germinal vesicle breakdown (GVBD) in meiosis I, can directly activate MAP kinase kinase in vitro and leads to the activation of MAPK in vivo. Recently we have shown that constitutively activated MAPK induces metaphase arrest when injected into one blastomere of a two-cell embryo. This arrest mimics the natural arrest of vertebrate unfertilized eggs in second meiotic metaphase due to cytostatic factor and c-Mosxe activity. We show here that microinjection of constitutively activated thiophosphorylated MAPK into resting oocytes is able to activate maturation-promoting factor (MPF) and promote GVBD. These results strongly support the hypothesis that MAPK plays an important role in the pathway that links c-Mosxe to the activation of MPF.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7729598     DOI: 10.1006/dbio.1995.1112

Source DB:  PubMed          Journal:  Dev Biol        ISSN: 0012-1606            Impact factor:   3.582


  38 in total

1.  Distinct, constitutively active MAPK phosphatases function in Xenopus oocytes: implications for p42 MAPK regulation In vivo.

Authors:  M L Sohaskey; J E Ferrell
Journal:  Mol Biol Cell       Date:  1999-11       Impact factor: 4.138

2.  A novel p34(cdc2)-binding and activating protein that is necessary and sufficient to trigger G(2)/M progression in Xenopus oocytes.

Authors:  I Ferby; M Blazquez; A Palmer; R Eritja; A R Nebreda
Journal:  Genes Dev       Date:  1999-08-15       Impact factor: 11.361

3.  Redundant pathways for Cdc2 activation in Xenopus oocyte: either cyclin B or Mos synthesis.

Authors:  Olivier Haccard; Catherine Jessus
Journal:  EMBO Rep       Date:  2005-12-16       Impact factor: 8.807

4.  Zinc maintains prophase I arrest in mouse oocytes through regulation of the MOS-MAPK pathway.

Authors:  Betty Y Kong; Miranda L Bernhardt; Alison M Kim; Thomas V O'Halloran; Teresa K Woodruff
Journal:  Biol Reprod       Date:  2012-07-01       Impact factor: 4.285

5.  Direct roles of the signaling kinase RSK2 in Cdc25C activation during Xenopus oocyte maturation.

Authors:  Ruoning Wang; Sung Yun Jung; Chuan Fen Wu; Jun Qin; Ryuji Kobayashi; Gary E Gallick; Jian Kuang
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-01       Impact factor: 11.205

6.  Xp38gamma/SAPK3 promotes meiotic G(2)/M transition in Xenopus oocytes and activates Cdc25C.

Authors:  Eusebio Perdiguero; Marie-Jeanne Pillaire; Jean-Francois Bodart; Florian Hennersdorf; Morten Frödin; Nicholas S Duesbery; Gema Alonso; Angel R Nebreda
Journal:  EMBO J       Date:  2003-11-03       Impact factor: 11.598

7.  A link between MAP kinase and p34(cdc2)/cyclin B during oocyte maturation: p90(rsk) phosphorylates and inactivates the p34(cdc2) inhibitory kinase Myt1.

Authors:  A Palmer; A C Gavin; A R Nebreda
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

8.  The adapter protein ZIP binds Grb14 and regulates its inhibitory action on insulin signaling by recruiting protein kinase Czeta.

Authors:  Bertrand Cariou; Dominique Perdereau; Katia Cailliau; Edith Browaeys-Poly; Véronique Béréziat; Mireille Vasseur-Cognet; Jean Girard; Anne-Françoise Burnol
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

9.  Dependence of Mos-induced Cdc2 activation on MAP kinase function in a cell-free system.

Authors:  C Y Huang; J E Ferrell
Journal:  EMBO J       Date:  1996-05-01       Impact factor: 11.598

10.  The Ras-GTPase-activating protein SH3 domain is required for Cdc2 activation and mos induction by oncogenic Ras in Xenopus oocytes independently of mitogen-activated protein kinase activation.

Authors:  M Pomerance; M N Thang; B Tocque; M Pierre
Journal:  Mol Cell Biol       Date:  1996-06       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.